Multiple Sclerosis and Cosmetic Surgery: Whether Anesthesia Triggers a Relapse, Why Heat and Infection Cause Pseudo-Relapses, Which MS Drugs Change the Surgical Plan, and Where Botox, Fat Grafting, and a Baclofen Pump Enter the Picture

The patient is 41, was diagnosed with relapsing-remitting multiple sclerosis eleven years ago, and has not had a relapse in six. They walk without a cane, work full time, and get an infusion twice a year. They want a breast lift and a small amount of liposuction, and they have been putting it off for three years because of one sentence a relative repeated at a holiday dinner: "Surgery can make MS worse."

The first surgeon they saw did not ask about the infusion. The second said they would need "clearance" and left it at that. The neurologist, when finally asked, said something more useful: the operation was reasonable, the timing relative to the next infusion mattered, the anesthesia team needed to know about the diagnosis in advance, and the most likely thing to go wrong was not a relapse at all but a few days of worse symptoms if the patient ran a fever or developed a bladder infection.

That gap between folklore and practical planning is the subject of this piece. Multiple sclerosis is an immune-mediated disease in which the protective myelin coating around nerves in the brain, spinal cord, and optic nerves is damaged, slowing or blocking electrical signals. It is not a contraindication to cosmetic surgery. It is a condition that changes how surgery should be timed, how the patient should be kept warm (but not too warm), which medications must never be interrupted, and who needs to talk to whom before the date is set. It builds on the earlier piece on cosmetic surgery with autoimmune disease, which covered lupus, rheumatoid arthritis, and scleroderma but left MS for its own treatment.

Does surgery or anesthesia trigger an MS relapse?

The short answer: there is no good evidence that general anesthesia itself causes MS relapses, the historical worry about spinal anesthesia rests on weak data, and the real timing rules are simpler: operate when the disease has been stable for several months, not during or soon after a relapse, and not while recovering from a course of high-dose steroids.

The belief that surgery worsens MS comes from older case reports and observational series in which patients relapsed after operations. The difficulty with that evidence is that MS relapses happen on their own, at a rate that varies from person to person, and any operation is a stressful event surrounded by infections, fevers, and sleep disruption. When researchers have looked more carefully, general anesthesia has not emerged as an independent trigger. Professional anesthesia references today treat general anesthesia in MS as acceptable, with attention to the specific issues below rather than avoidance.

Stress is a separate and more credible factor. A meta-analysis published in the BMJ in 2004 found an association between stressful life events and subsequent relapses, though the effect was modest and the mechanism uncertain. Elective surgery is a planned stress, which means it can be scheduled away from other planned stresses: a move, a job change, a bereavement, the postpartum months. That is a planning point, not a reason to avoid surgery.

Spinal anesthesia is the area where caution persists. The theory is that demyelinated nerve tissue in the spinal cord may be more sensitive to local anesthetic, and spinal anesthesia places the drug directly into the fluid around the cord. Evidence for actual harm is thin, and epidural anesthesia, which delivers lower concentrations, has been studied more reassuringly, including in the large PRIMS study of pregnancy in MS, published in the New England Journal of Medicine in 1998, which found that epidural analgesia during delivery did not worsen the course of the disease. Most cosmetic operations are done under general anesthesia or sedation with local anesthetic anyway, a choice covered in the piece on anesthesia and the operative plan, so this is rarely the deciding question.

There is one anesthesia drug where MS changes practice. Succinylcholine, a fast-acting muscle relaxant used to place breathing tubes, can cause a dangerous surge in blood potassium in patients whose muscles have been weakened or immobilized by nerve disease. Anesthesiologists generally avoid it in MS patients with significant weakness, which is one of several reasons the anesthesia team should know about the diagnosis before the morning of surgery, not discover it on the intake form.

"

The question is rarely whether a person with MS can have cosmetic surgery. It is whether anyone on the surgical team has asked when their last relapse was, what drug they take, and when their next dose is due.

"

The timing rules most neurologists apply to elective surgery look like this:

• Not during an active relapse. New or worsening neurological symptoms lasting more than a day or two need evaluation, not an operating room.
• Not soon after high-dose steroids. Relapses are commonly treated with a few days of high-dose intravenous methylprednisolone or an oral equivalent. Steroids at those doses impair wound healing, raise blood sugar, and suppress immunity for a period afterward. The earlier pieces on steroids for swelling after surgery and blood sugar and cosmetic surgery explain why a recent high-dose course is a reason to wait, typically several weeks at minimum.
• After a period of stability. Many neurologists prefer several months without a relapse and without new activity on the most recent MRI before an elective operation. There is no universal number, which is why the neurologist's opinion belongs in the chart.
• Coordinated with the treatment calendar. Infusions and dosing cycles, covered below, often determine the ideal window.

Heat, fever, and infection: the pseudo-relapse problem

The short answer: in MS, a rise in body temperature from fever, infection, a hot environment, or even excessive warming can temporarily worsen old symptoms or bring back ones the patient thought were gone, a phenomenon called a pseudo-relapse, and it is far more common around surgery than a true relapse.

Damaged myelin conducts electrical signals less reliably, and that reliability gets worse as temperature rises. The effect was first described by the German ophthalmologist Wilhelm Uhthoff in 1890, who noticed that some patients' vision blurred during exercise, and it now carries his name. A small increase in core temperature can be enough to cause blurred vision, numbness, weakness, fatigue, or balance problems in a patient whose nerves are already working near their margin. When the temperature falls, the symptoms usually resolve within hours to a day or so, because no new damage has occurred.

A pseudo-relapse looks frightening to a patient who has spent years watching for relapses. The surgical team's job is to anticipate it and to distinguish it from a true relapse, which involves new inflammation and usually lasts much longer. The common surgical triggers are:

• Fever. Low-grade temperatures in the first two days after surgery are common and usually reflect normal inflammation, as discussed in the piece on fever after plastic surgery. In an MS patient, even a modest fever can produce a temporary flare of symptoms, so fever control matters more than usual.
• Urinary tract infections. Bladder dysfunction is common in MS, and anesthesia and opioids add to the risk of incomplete emptying, the problem covered in the piece on urinary retention after plastic surgery. Retained urine leads to infection, and infection is one of the most frequent causes of pseudo-relapse. A patient with known bladder symptoms should have a specific plan for voiding after surgery, and anyone who uses intermittent self-catheterization should say so at the consultation.
• Wound infections and chest infections. Any infection raises temperature. Shallow breathing and reduced mobility after surgery raise the risk of chest infection, especially in patients with weakness.
• Warming that overshoots. Operating rooms work hard to prevent hypothermia, for good reason: the piece on shivering and hypothermia after surgery explains how a cold patient bleeds more and heals worse. The target for an MS patient is the same normal temperature, but forced-air warming blankets left running after the patient is warm can push them past it. Asking the anesthesia team to monitor temperature continuously and aim for normal, not generous, is a reasonable request.
• Compression garments in hot weather. A tight, layered garment after liposuction or a tummy tuck, worn through a summer heat wave, is a small heat load around the clock. The garment still matters, for reasons covered in the piece on compression garment evidence, but breathable fabrics, a cool room, and fans are part of the plan.
• Hot showers and baths. Long hot showers in the first weeks can trigger symptoms. Lukewarm water is the simpler rule.

Cold is the opposite case. Many people with MS feel better in cooler conditions, and cold therapy after surgery, used sensibly, rarely causes a problem, though some patients with sensory symptoms cannot judge temperature well and need to protect numb skin from ice injury.

The MS drugs that change the surgical plan

The short answer: disease-modifying therapies should almost never be stopped for cosmetic surgery without the neurologist's direct involvement, because some carry a risk of rebound disease activity when interrupted, while others affect infection risk, blood counts, or bleeding in ways the surgical team needs to know about in advance.

Disease-modifying therapies, often shortened to DMTs, reduce relapses and slow disability by altering the immune system. There are now more than twenty approved in the United States, and they differ enough that a single "MS drug" rule does not exist. The groups that matter most for surgery are:

• B-cell depleting infusions and injections (ocrelizumab, ofatumumab, ublituximab, and rituximab used off-label). These deplete a type of immune cell for months at a time. They raise the risk of infections, and with prolonged use some patients develop low antibody levels. Infusions are usually given every six months, and neurologists often prefer to schedule elective surgery well away from the infusion itself, with the surgery date agreed in advance so neither is delayed by the other.
• Natalizumab. A monthly infusion that blocks immune cells from entering the brain. Stopping it, even for a few months, can lead to a return of disease activity, sometimes more severe than before treatment. A missed dose to accommodate surgery should be a neurologist's decision, not a scheduling convenience.
• S1P receptor modulators (fingolimod, siponimod, ozanimod, ponesimod). These trap immune cells in lymph nodes, lowering circulating lymphocyte counts. The FDA added a warning in 2018 that stopping fingolimod can cause a severe increase in disability in some patients. These drugs can also slow the heart rate, particularly when started or restarted, which matters to an anesthesia team.
• Alemtuzumab. Given in courses, with blood monitoring required for years afterward because a minority of patients develop immune thrombocytopenia, a low platelet count that causes bleeding, and a substantial share develop thyroid disease. A patient who has received alemtuzumab should bring recent blood counts and thyroid results to the pre-operative testing visit.
• Cladribine. Oral courses that lower lymphocyte counts for months. Surgery timing relative to the most recent course is a question for the neurologist.
• Teriflunomide and dimethyl fumarate. Oral daily drugs. Teriflunomide can affect the liver and lingers in the body for a long time. Dimethyl fumarate can lower lymphocyte counts and causes flushing that patients sometimes mistake for a surgical reaction.
• Interferon beta and glatiramer acetate. Older injectable drugs with a long safety record. Their surgical relevance is mostly at the skin, covered in the next section.

Several other medications common in MS also belong on the list:

• Baclofen. Used for spasticity. Oral baclofen should not be stopped abruptly, because withdrawal can cause hallucinations, seizures, and rebound spasticity. Patients who are told to fast before surgery sometimes skip it; they should ask for a specific instruction. Intrathecal baclofen, delivered by an implanted pump, carries an FDA boxed warning: abrupt interruption can cause high fever, rigidity, and in rare cases death.
• Dalfampridine. Used to improve walking. It lowers the seizure threshold and is cleared by the kidneys, so it is handled carefully when kidney function or other medications change.
• Gabapentin, pregabalin, and antidepressants for nerve pain. Usually continued. They add sedation when combined with postoperative opioids, one reason an opioid-sparing recovery plan suits MS patients particularly well.
• Biotin. Many people with MS take high-dose biotin after early studies suggested benefit in progressive disease, even though a later large trial did not confirm it. The FDA has warned that biotin can interfere with laboratory tests, including thyroid tests and troponin, a marker of heart injury. It belongs on the list in the piece on supplements to stop before surgery, mainly so that test results can be trusted.

The practical rule is simple: bring a complete written medication list, including the date of the last infusion or course, and ask the surgeon to send the operative plan to the neurologist before the date is booked. A neurologist's note that says "proceed, schedule between weeks eight and twelve after infusion, continue all oral medications" is worth more than any amount of generic "clearance."

Where MS and cosmetic procedures meet directly

The short answer: beyond general surgical risk, MS intersects with cosmetic care at several specific points, including neurotoxin dosing for patients who already receive botulinum toxin for spasticity or bladder symptoms, injection-site fat loss from older MS drugs, baseline facial numbness and weakness that can be confused with surgical injury, implanted baclofen pumps in the abdomen, and the regular MRI scans most patients need.

Botox and other neurotoxins. Botulinum toxin is not just a cosmetic drug in MS. The FDA has approved onabotulinumtoxinA for spasticity and for bladder overactivity caused by neurological disease, including MS, at doses far larger than any cosmetic treatment. MS is not a disease of the junction between nerve and muscle, the setting where neurotoxins carry special warnings, so cosmetic doses are generally considered acceptable. But a patient who receives therapeutic injections should tell the injector, because total dose and spacing between treatments matter, and repeated large exposures are one of the theories behind resistance, discussed in the piece on why Botox stops working. Patients with any swallowing difficulty, which some people with MS develop, warrant extra caution around neck treatments in particular.

Injection-site lipoatrophy. Glatiramer acetate and, less often, interferon beta can cause localized fat loss at injection sites on the thighs, abdomen, upper arms, and buttocks, sometimes leaving visible dents after years of injections. This is one of the few places where MS directly creates a cosmetic concern. Fat grafting and fillers have both been used to correct it, with the same principles that apply to other fat loss conditions in the piece on facial lipoatrophy. The scarred, thin tissue at injection sites can make grafts take less predictably, for the reasons explained in the piece on fat graft survival, and switching to a drug that does not cause the problem is usually discussed with the neurologist first.

Facial numbness, weakness, and pain. MS can cause patches of facial numbness, facial weakness that resembles Bell's palsy, and trigeminal neuralgia, a severe stabbing facial pain that is more common in MS than in the general population. Facelifts, brow lifts, and rhinoplasty all cause temporary numbness of their own, as covered in the piece on numbness after plastic surgery. Without careful baseline documentation, a patient and a surgeon can end up arguing over whether a new symptom came from the operation or the disease. Photographs of facial movement and a written sensory examination before surgery protect both. A patient with a history of facial weakness should also understand how recovery from nerve injury works, as described in the piece on synkinesis and facial reanimation.

Eyes and eyelids. Optic neuritis, often the first sign of MS, can leave lasting changes in vision, and some patients have double vision from eye movement problems. Neither rules out eyelid surgery, but both should be documented beforehand, and patients with incomplete eyelid closure or reduced blinking from facial weakness are at greater risk of the problem covered in the piece on dry eye after eyelid surgery.

Baclofen pumps and abdominal surgery. An intrathecal baclofen pump sits under the skin of the lower abdomen, with a catheter tunneling around the flank to the spine. A tummy tuck or abdominal liposuction in a patient with a pump requires planning with the team that manages it: the pump's position, the catheter's path, and the refill schedule all affect where a surgeon can safely work. Damaging the catheter can interrupt delivery, which is the scenario the boxed warning exists for.

MRI scans and implants. People with MS typically have regular brain and spine MRIs. Silicone and saline breast implants are generally compatible with MRI, though breast tissue expanders with magnetic ports are not, a distinction worth confirming for anyone considering reconstruction. The piece on breast imaging after implants covers how implants affect imaging more broadly. Patients should keep the implant card and tell the MRI center about any implanted device.

Recovery: clots, fatigue, mobility, and choosing the right setting

The short answer: recovery from cosmetic surgery with MS is usually slower and more tiring than for other patients, with a higher baseline risk of blood clots when mobility is limited, a greater need for help at home, and a stronger case for an accredited facility and a conservative scope of surgery.

Blood clots. Studies have found a higher risk of venous thromboembolism in people with MS, concentrated among those with reduced mobility. Surgery adds its own risk. The prevention measures in the piece on blood clots after plastic surgery, including early walking, compression devices, and medication for higher-risk patients, apply with more force. A patient who uses a cane or wheelchair should expect a formal risk score and a deliberate decision about blood thinners, not a default.

Fatigue. MS fatigue is one of the most common and disabling symptoms of the disease, and anesthesia, pain, interrupted sleep, and wound healing all draw on the same reserve. Patients should plan for a longer return to work than the surgeon's standard estimate. Short-lived difficulty with concentration and memory after anesthesia, discussed in the piece on brain fog after anesthesia, can feel more alarming for someone who already lives with cognitive symptoms, and it usually fades on the same timeline.

Mobility and help at home. Balance problems, weakness, and spasticity make the first days after surgery harder: getting out of bed with abdominal tightness, using a bathroom with arms restricted after breast surgery, managing drains. A caregiver plan matters more, as described in the piece on recovery houses and the first 72 hours. Combining several operations in one long session magnifies all of these problems, which is a strong argument for staging procedures rather than combining them.

Mood. Depression is common in MS, and the post-operative low that many patients experience regardless of diagnosis, covered in the piece on emotional recovery after plastic surgery, can be deeper for someone already managing it. Continuing antidepressants and keeping existing support in place are part of the plan.

Pregnancy and postpartum timing. The PRIMS study found that relapse rates fall during pregnancy, especially in the third trimester, and rise in the first three months after delivery. For mothers with MS considering surgery after pregnancy, the period of higher relapse risk is another reason to wait, beyond the reasons laid out in the piece on mommy makeover timing.

The facility. Many office-based surgical suites accept only patients classified as ASA I or II, meaning healthy or with mild, well-controlled systemic disease. A person with stable MS and minimal disability often fits that description. A person with significant weakness, swallowing difficulty, breathing limitation, or bladder dysfunction requiring catheterization is more likely ASA III, which points toward a hospital or ambulatory surgery center with greater resources. The piece on outpatient facility accreditation explains what those classifications mean in practice.

The honest summary

Multiple sclerosis does not rule out cosmetic surgery, and the folk belief that anesthesia sets off relapses is not supported by good evidence. What MS does require is a plan built around the disease rather than one that ignores it. Elective surgery belongs in a stable period, not during a relapse or soon after high-dose steroids. The anesthesia team needs to know in advance, for reasons that include muscle relaxant choice and temperature control.

The most likely problem after surgery is not a relapse but a pseudo-relapse: a temporary return of old symptoms driven by fever, infection, or heat. Preventing bladder infections, controlling fever, aiming for a normal body temperature rather than a warm one, and keeping compression garments and showers from overheating the patient are simple measures that prevent most of it.

Disease-modifying drugs should not be paused for a cosmetic operation without the neurologist, because several can rebound when interrupted, while others affect infection risk, blood counts, or bleeding. Baclofen should never be stopped abruptly, and patients with pumps need coordination before any abdominal procedure. Where MS meets cosmetic care directly, through therapeutic neurotoxin injections, injection-site fat loss, baseline facial symptoms, and regular MRIs, good documentation and communication do most of the work.

The patient at the top of this piece went ahead. The surgery was scheduled ten weeks after an infusion, the neurologist and anesthesiologist both had the plan in writing, and the only post-operative symptom was a day of tingling in one leg during a hot afternoon, which faded once the room was cooled. That is what a well-planned operation with MS usually looks like: unremarkable, because someone did the remarkable part in advance.